Seroprevalence of anti-mumps virus IgG antibody titer and voluntary mumps vaccination coverage in young adults in Japan

Sasaki, Hiraku; Fukunaga, Tomoko; Asano, Ai; Yamanaka, Kansuke; Oikawa, Kota; Shibata, Nobuto

doi:10.1080/21645515.2021.1913967

Cited by 4 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 The most commonly used MuCV globally is trivalent live attenuated measles, mumps, and rubella (MMR) vaccine. 6 In China, MMR has been included in the national routine program for immunization since 2008. 7 MMR was introduced on 1 April 2008 in Fujian province.…”

Section: Introductionmentioning

confidence: 99%

Mumps serological surveillance following 10 years of a one-dose mumps-containing-vaccine policy in Fujian Province, China

Liu¹,

Zhang²,

You

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Background Since 2008, Fujian province provided measles-rubella (MR) vaccine at 8 months followed by measles-mumps-rubella (MMR) vaccine at 18 months a one-dose mumps-containing-vaccine (MuCV) schedule. Several mumps outbreaks have occurred recently in Fujian. Serological surveillance can assess population immunity to mumps and identify risk factors for mumps. Methods We conducted a cross-sectional serosurvey of mumps IgG antibodies in the general population of Fujian Province in 2018 and compare results with a similar study conducted in 2009, when the routine schedule had no MuCV. We analyzed changes in mumps epidemiology after implementation of a one-dose MuCV vaccination strategy. Results Mumps seroprevalence was 78.6% (95% CI: 77.4–79.8), and the geometric mean concentration (GMC) of mumps antibodies was 245.8 IU/ml (95% CI:237.3–255.1). MuCV vaccination at 18 months resulted in increased seroprevalence and GMCs. Seroprevalence and GMCs varied by age, gender, and number of doses received. Except for children under 18 months, seroprevalence and GMCs were lowest among 10-15-year-olds. Each year after introduction of the one-dose MuCV vaccination policy, the highest incidence of mumps was among 4–6-year-olds and 9–15-year-olds, gradually shifting to older age groups. Conclusion A one-dose mumps-containing vaccine schedule does not provide sustained and stable mumps immunity in Fujian. To reduce the risk of mumps, we recommend supplementary vaccination of children without a history of receiving at least one MuCV dose or who are seronegative at 10–15 years of age.

show abstract

Section: Introductionmentioning

confidence: 99%

Mumps serological surveillance following 10 years of a one-dose mumps-containing-vaccine policy in Fujian Province, China

Liu¹,

Zhang²,

You

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Other researchers reported a rate of 4.3% (11 students) among 1st-year Japanese university students without a mumps infection history. 15 The rates of second and later doses of mumps vaccination have remained low for a decade and do not satisfy the 85–90% requirement for herd immunization. 2 The World Health Organization recommends the second dose of MMR vaccinations.…”

Section: Discussionmentioning

confidence: 99%

Mumps vaccination and immune status among Japanese university students: A multicenter cross-sectional study

Takeuchi,

Ozaki,

Hata

et al. 2024

Journal of Public Health Research

View full text Add to dashboard Cite

Background: During the mumps outbreak in Japan in 2016, 159,031 cases were reported. In a survey conducted in 2015, mumps vaccination rates for the first dose were 30%–40%. However, the rates for two or more doses were not determined. We assessed the mumps vaccination rates and mumps infection prevalence according to vaccine doses received. Design and methods: This was a multicenter cross-sectional study. Students from three universities participated in 2019. Informed consent was obtained from the students and their guardians. The primary outcome was the prevalence of breakthrough mumps infection according to the number of doses of vaccine received. We collected data on past illnesses of vaccine-preventable diseases and vaccination history using a questionnaire, photocopies of the Maternal and Child Health Handbook from the guardians, and virus antibody titers from the universities’ health centers. Results: This study assessed 2004 eligible students and included 593 (29.6%); of these, 250 (42.7%) had a mumps infection history. Furthermore, 264 (44.6%), 31 (5.2%), and 2 (0.3%) students received the first, second, and third doses of mumps vaccine, respectively. The mumps seropositivity prevalence was 43.2% ( n = 127), 36.7% ( n = 97), 26.7% ( n = 8), and 100% ( n = 2) for the no-, first-, second-, and third-dose groups, respectively ( p for trend = 0.09). The mumps infection prevalence rates were 69.8% ( n = 203), 11.3% ( n = 28), 3.9% ( n = 1), and 0% for the no-, first-, second-, and third-dose groups, respectively. Conclusions: Approximately 1 in 10 students who had received only one dose of mumps-containing vaccine had a breakthrough infection history.

show abstract

Epidemiological characteristics and serological survey of mumps 15 years after MMR vaccine was included in the immunization program

Gong,

Fang,

Zheng

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

Mumps is a vaccine‐preventable acute viral infectious disease. To understand the incidence of mumps and population immunity in Quzhou City after measles mumps rubella vaccine (MMR) was included in the immunization program, we analyzed the epidemiological characteristics of mumps cases from 2009 to 2023 and a cross‐sectional serosurvey of IgG antibodies to mumps conducted in 2024. We found that 15 years after the MMR vaccine was included in the immunization program, the incidence of mumps was significantly reduced in all populations, but the incidence remained highest in vaccinated children aged 0–12 years. Vaccine escape may explain the high incidence of mumps in highly vaccinated populations. Updating vaccines or developing a new vaccine that targets multiple viral genotypes may be necessary to improve the effectiveness of the vaccine against infection and fully control infections and outbreaks. The positive rate and concentration of mumps IgG antibody were inconsistent with the incidence data. mumps IgG antibody is not an ideal substitute for immunity and cannot be used to accurately predict whether a target population is susceptible or protected. Natural infections may provide longer‐lasting immunity than vaccination.

show abstract

Seroprevalence of anti-mumps virus IgG antibody titer and voluntary mumps vaccination coverage in young adults in Japan

Cited by 4 publications

References 12 publications

Mumps serological surveillance following 10 years of a one-dose mumps-containing-vaccine policy in Fujian Province, China

Mumps serological surveillance following 10 years of a one-dose mumps-containing-vaccine policy in Fujian Province, China

Mumps vaccination and immune status among Japanese university students: A multicenter cross-sectional study

Epidemiological characteristics and serological survey of mumps 15 years after MMR vaccine was included in the immunization program

Contact Info

Product

Resources

About